

## SPECIALTY GUIDELINE MANAGEMENT

### ACTEMRA (tocilizumab)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indications

1. Moderately to severely active rheumatoid arthritis
2. Active polyarticular juvenile idiopathic arthritis
3. Active systemic juvenile idiopathic arthritis
4. Giant cell arteritis

###### B. Compendial Uses

1. Unicentric Castleman's disease
2. Multicentric Castleman's disease

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. CRITERIA FOR INITIAL APPROVAL

###### A. **Moderately to severely active rheumatoid arthritis (RA)**

1. Authorization of 24 months may be granted for members who have previously received Actemra or any other biologic DMARD or targeted synthetic DMARD (e.g., Xeljanz) indicated for moderately to severely active rheumatoid arthritis.
2. Authorization of 24 months may be granted for treatment of moderately to severely active RA when any of the following criteria is met:
  - a. Member has experienced an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to 20 mg/week).
  - b. Member has an intolerance or contraindication to methotrexate (see Appendix).

###### B. **Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)**

1. Authorization of 24 months may be granted for members who have previously received Actemra or Orencia.
2. Authorization of 24 months may be granted for treatment of active pJIA when any of the following criteria is met:
  - a. Member has experienced an inadequate response to at least a 3-month trial of a TNF inhibitor (e.g., Enbrel, Humira, or Remicade).
  - b. Member has experienced an intolerance or has contraindication to a TNF inhibitor.

#### Actemra SQ

---

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

**C. Active Systemic Juvenile Idiopathic Arthritis (sJIA)**

1. Authorization of 24 months may be granted for members who have previously received Actemra or Kineret.
2. Authorization of 24 months may be granted for treatment of active sJIA when any of the following criteria is met:
  - a. Member has an inadequate response to at least a 2-week trial of corticosteroids.
  - b. Member has an inadequate response to at least a 3-month trial of methotrexate or leflunomide.

**D. Giant Cell Arteritis**

Authorization of 12 months may be granted for treatment of giant cell arteritis.

**E. Unicentric and Multicentric Castleman's Disease**

Authorization of 12 months may be granted for treatment of unicentric or multicentric Castleman's disease.

**III. CONTINUATION OF THERAPY**

**A. Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis**

Authorization of 24 months may be granted for all members (including new members) who meet all initial authorization criteria and achieve or maintain positive clinical response after at least 3 months of therapy with Actemra as evidenced by low disease activity or improvement in signs and symptoms of the condition.

**B. Giant Cell Arteritis**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

**C. Unicentric and Multicentric Castleman's Disease**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

**IV. OTHER**

For all indications: Member has a pretreatment tuberculosis (TB) screening with a TB skin test or an interferon gamma release assay (e.g., QFT-GIT, T-SPOT.TB)

Note: Members who have received Actemra or any other biologic DMARD or targeted synthetic DMARD (e.g., Xeljanz) are exempt from requirements related to TB screening in this Policy.

**V. APPENDIX: Examples of Contraindications to Methotrexate**

1. Alcoholism, alcoholic liver disease or other chronic liver disease
2. Breastfeeding
3. Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia)
4. Elevated liver transaminases
5. History of intolerance or adverse event
6. Hypersensitivity
7. Interstitial pneumonitis or clinically significant pulmonary fibrosis
8. Myelodysplasia
9. Pregnancy or planning pregnancy (male or female)

10. Renal impairment
11. Significant drug interaction

## VI. REFERENCES

1. Actemra [package insert]. South San Francisco, CA: Genentech, Inc.; May 2018.
2. National Comprehensive Cancer Network. The NCCN Drugs & Biologics Compendium. <http://www.nccn.org>. Accessed July 26, 2017.
3. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
4. Smolen JS, Landewé R, Billsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017;0:1-18.
5. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res*. 2011;63(4):465-482.
6. Ringold S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. *Arthritis & Rheumatism*. 2013;65:2499-2512.